Cold Agglutinin Disease
2017
Berentsen et al, prospective study using BR: 71% RR, 40% CR, 31% PR. 50% RR in the retreatment setting. TTR 2mo. 77% response rate at 5y. Median DOR >88mo.
2018
Rossi et al report on 2L bortezomib (GIMEMA) (single cycle): 32% RR, median DOR 16mo.
2020, 2021
Case reports on CAS d/t pembro (Atiq 2020) and atezo (Acikgoz 2021).